Olaparib maintenance
Checked 2026-09-09
Newly diagnosed BRCA-mutant advanced ovarian cancer after platinum response (2 years); recurrent platinum-sensitive disease; BRCA/HRR-mutant prostate; germline BRCA pancreatic after platinum
One cycle
every 28 days × 2 · about 8 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Olaparib Small-molecule PARP inhibitor | 300 mg twice daily | Oral | D1-28 |
Cycles
2 years (SOLO-1) or until progression
28-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Not routine
Notes
- Anaemia is the commonest dose-limiting toxicity; check blood counts monthly for the first year.
Used in
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
mFOLFOX6
Adjuvant stage III colon (6 months) or metastatic colorectal and upper GI first line
every 14 days × 12
FOLFIRINOX
Metastatic pancreatic cancer, performance status 0-1
every 14 days × 12
mFOLFIRINOX (adjuvant)
Resected pancreatic cancer, fit patients, started within 12 weeks of surgery
every 14 days × 12
Gemcitabine + nab-paclitaxel
Metastatic pancreatic cancer first line; adjuvant option when FOLFIRINOX is not tolerated
every 28 days
Gemcitabine monotherapy
Frail patients or adjuvant when combinations are not tolerated
every 28 days × 6
NALIRIFOX
Metastatic pancreatic cancer first line
every 14 days
Topotecan
Relapsed SCLC; platinum-resistant ovarian or cervical cancer
every 21 days
Docetaxel + prednisone
Metastatic hormone-sensitive (with ADT, 6 cycles: CHAARTED, ARASENS) or castration-resistant prostate cancer
every 21 days × 6